Research Article
Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry
Table 3
Baseline characteristics of subjects with familial hypercholesterolemia by cascade screening.
| | Possible ( (73.6%)) | Probable ( (12.4%)) | Definite ( (14.0%)) | Definite and probable ( (26.4%)) | Total () |
| Demographics | | | | | | Sex (male) | 46 (48.4) | 8 (50.0) | 8 (44.4) | 16 (47.1) | 62 (48.1) | Age (years) | | | | | | Family history of premature CVDa | 39 (41.1) | 7 (43.8) | 3 (16.7) | 10 (29.4) | 49 (38.0) | Smoking status | | | | | | Never | 80 (84.2) | 13 (81.3) | 15 (83.3) | 28 (82.4) | 108 (83.7) | Current | 9 (9.5) | 3 (18.8) | 2 (11.1) | 5 (14.7) | 14 (10.9) | Previous | 6 (6.3) | 0 (0.0) | 1 (5.6) | 1 (2.9) | 7 (5.4) | Presence of Achille tendon | 0 (0) | 0 (0) | 4 (23.5) | 4 (12.1) | 4 (3.1) | Xanthomas | 0 (0) | 0 (0) | 8 (47.1) | 8 (24.2) | 8 (6.3) | Arcus cornealis | 0 (0) | 1 (6.3) | 2 (11.1) | 3 (8.8) | 3 (2.3) | Body mass index (kg/m2) | | | | | | Comorbidities | | | | | | Hypertension | 24 (25.3) | 2 (12.5) | 1 (5.6) | 3 (8.8) | 27 (20.9) | Diabetes mellitus | 13 (13.8) | 2 (12.5) | 5 (27.8) | 7 (20.6) | 20 (15.6) | History of CVD | 31 (33.0) | 1 (6.3) | 5 (27.8) | 6 (17.6) | 37 (28.9) | Biochemical measures | | | | | | Total cholesterol (mg/dl) | | | | | | LDL-cholesterolb (mgr/dl) | | | | | | HDL-cholesterolc (mgr/dl) | | | | | | Non-HDL cholesterol (mg/dl) | 173.09-55.31 | | | | | Triglycerides (mgr/dl) | | | | | | FBSd | | | | | | HbA1ce | | | | | | History of medication use | | | | | | Lipid-lowering drugs | 38 (40.0) | 9 (56.3) | 12 (66.7) | 21 (61.8) | 59 (45.7) | Antihypertensive | 22 (23.2) | 3 (18.8) | 1 (5.6) | 4 (11.8) | 26 (20.2) | Antidiabetics | 8 (8.4) | 1 (6.3) | 2 (11.1) | 3 (8.8) | 11 (8.5) | Aspirin | 12 (12.6) | 2 (12.5) | 1 (5.6) | 3 (8.8) | 15 (11.6) |
|
|
aCVD: cardiovascular disease. bLDL-cholesterol: low-density lipoprotein cholesterol. cHDL-cholesterol: high-density lipoprotein cholesterol. dFBS: fast blood sugar. eHbA1c: hemoglobin A1c.
|